Navigation Links
Johns Hopkins neuroscientists win National Academy of Science Awards
Date:1/14/2013

Solomon H. Snyder, M.D., has won the National Academy of Sciences (NAS) Award in Neurosciences, and King-Wai Yau, Ph.D., has won the Alexander Hollaender Award in Biophysics, the NAS has announced. Both of these prestigious awards are offered only once every three years. Snyder and Yau will receive the awards on Sunday, April 28, during the Academy's 150th annual meeting.

"We are very proud to have two of our neuroscience faculty win awards from NAS in the same year," says Richard Huganir, Ph.D., director of the Solomon H. Snyder Department of Neuroscience. "Sol has contributed more to the field of molecular neuroscience than anyone in the world and is one of the luminaries in the field, and King's rigorous physiological and molecular approach has made him the preeminent biophysicist in vision research."

Snyder, a professor of neuroscience and former director of the eponymous Solomon H. Snyder Department of Neuroscience at the Institute for Basic Biomedical Sciences at the Johns Hopkins University School of Medicine, was recognized for groundbreaking discoveries ranging from the discovery of opiate receptors in the brain to proof that gases such as nitric oxide can serve as messengers between neurons. Many advances in molecular neuroscience have stemmed from Snyder's identification of receptors that neurons have for messenger molecules and some medications, a find which led to clarification of how these drugs work in the brain. His award comes with a $25,000 cash prize.

Yau, a professor of neuroscience and ophthalmology, was recognized for his work on vision. He discovered that two signaling molecules, calcium and cyclic GMP, convert light into electrical signals in the retina's rod and cone photoreceptor cells. This work led to a greater understanding of hereditary blinding diseases that affect rod and cone cells. By characterizing the light-response behaviors of a new type of photoreceptor cell in the retina, Yau found these cells a
'/>"/>

Contact: Vanessa McMains
vmcmain1@jhmi.edu
410-502-9410
Johns Hopkins Medicine
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. US Drug Watchdog Now Urges Families Of Diabetics Diagnosed with Bladder Cancer To Call The Johnson Law Group If They Used the Diabetes Drug Called Actos
2. US Drug Watchdog Now Urges Users of Yaz or Yasmin Birth Control Pills Who Suffered A Life Threatening Medical Problem To Call The Johnson Law Group-Immediately
3. US Drug Watchdog Now Urges Family Members Mourning The Loss Of A Loved One Who Developed Bladder Cancer After Using The Diabetes Drug Actos To Call The Johnson Law Group
4. The US Drug Watchdog Now Urges Users Of The Birth Control Pills Yaz-Yasmin to Contact The Johnson Law Group For a Legal Review if They Developed Severe Medical Problems
5. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
6. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
7. US Drug Watchdog Is Expanding Their Yaz-Yasmin Birth Control Pill Initiative and They Urge Victims to Contact the Johnson Law Group if They Had a Heart Attack or Stroke
8. Johns Hopkins receives funding for cholera vaccine initiative
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. A Serious Problem: Medical Malpractice Lawyers at Console & Hollawell React to Alarming Doctor Error Statistics from Johns Hopkins University Researchers
11. US Drug Watchdog Now Fears Most Women Never Heard About Yaz or Yasmin Birth Control Pill Side Effects and They Urge to Victims to Call the Johnson Law Group-Get Help Now
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Johns Hopkins neuroscientists win National Academy of Science Awards
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... 2014 The Advocator Group, LLC ... the American Foundation for Suicide Prevention’s (AFSP) Out of ... a not-for-profit organization that hosts hundreds of community walks ... events are used to help understand and prevent suicide ... relationships as well. , The Advocator Group shares ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
(Date:10/20/2014)... Angeles, CA (PRWEB) October 20, 2014 ... fitness expertise, nutritional coaching, corporate wellness programming, authorship, international ... CPT, is excited to announce the release of the ... , After many years of coaching thousands of individuals ... nutrition tracking app that does not require calorie counting ...
Breaking Medicine News(10 mins):Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3
... Researchers at the University of Pennsylvania School of ... associated with familial Alzheimer,s disease disrupt the flow ... called PS1 and PS2 (presenilin 1 and 2), ... intracellular cell compartment. , "The ,calcium dysregulation, hypothesis ...
... Without immediate action to develop an integrated, comprehensive, national health ... status as the global health care leader, states a new ... www.aahcdc.org ). The report was funded in part ... Out of Time: The State of the Nation,s Health Workforce ...
... cancer patients develop resistance to chemotherapy drugs, sometimes abruptly, ... be working well to reduce tumors or hold them ... the result when this occurs is all too familiar: ... cancers become resistant. , A team of researchers at ...
... Baxa Corporation, a,Denver-based manufacturer of medical devices and ... the release,of a newly designed Web site for ... The online forum, known as eBUG for,electronic Baxa ... along,with creating a virtual ,community, for sharing pharmacy ...
... SIOUX FALLS, S.D., July 18 William S.,Harris, ... letter,dated July 16:, Eating fish, especially oily ... heart disease prevention. Fish is low in total ... minerals, and contains,long-chain omega-3 fatty acids (EPA and ...
... YORK, July 18 Standing Tall announced today ... Board of Directors., "Standing Tall has created ... the most severely disabled children in New York ... gain mobility and independence,by actively using their bodies ...
Cached Medicine News:Health News:Calcium may be the key to understanding Alzheimer's disease 2Health News:Calcium may be the key to understanding Alzheimer's disease 3Health News:New report warns current policies will not avert health workforce crisis 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 4Health News:Baxa Corporation Launches New Electronic Users' Group Web Site 2Health News:An Open Letter Regarding Recent Reports That Low-Fat Fish Like Tilapia Are Unhealthy (July 16, 2008) 2Health News:An Open Letter Regarding Recent Reports That Low-Fat Fish Like Tilapia Are Unhealthy (July 16, 2008) 3Health News:Bernadette Peters Joins Board of Directors of Standing Tall, Innovative Program for Multiply Disabled Children 2
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... VIEW, Calif. , Oct. 22, 2014 ... a.m. EDTLOCATION: Online, complimentary registration available at: ... Team Leader Archana Vidyasekar and Visionary Innovation ... computers, WiFi-like wireless electricity, self-assembling materials, nanobots ... ten technologies which will transform our lives ...
(Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... (NYSE: VAR ) will showcase radiosurgery technologies ... non-invasively at the 2012 International Conference of the American ... "We,re excited about putting our technology ... with radiosurgery as a treatment option for early-stage, inoperable ...
... 2012 OrbusNeich today announced that two subgroup ... of the company,s Combo Dual Therapy Stent versus ... with the Combo Stent.  Presented at EuroPCR 2012, ... tomography (FD-OCT) and virtual histology-intravascular ultrasound (VH-IVUS) at ...
Cached Medicine Technology:Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 2Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 3Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: